Eloxx Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ELOX | PRQR | EDSA | ATYR | TOVX | ELDN | |
|---|---|---|---|---|---|---|
| Market cap | 56.07M | 228.61M | 39.72M | 21.07M | 10.07M | 198.28M |
| P/E (TTM) | 3.9 | — | — | — | 0.3 | — |
| Forward P/E | -19.6 | -3.4 | — | -0.5 | -1.1 | -3.2 |
| Price/book | 1.2 | 2.6 | 71.7 | 0.4 | 0.8 | 2.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +24.80% | −28.82% | +38.19% | −79.33% | −51.11% | −8.82% |
| Today | +1.09% | −0.61% | −16.24% | −12.75% | +1.11% | −1.61% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ELOX news ›Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Falls 5.2% – Here’s What Happened
Posted by Defense World Staff on Oct 7th, 2026 Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report)’s share price fell 5.2% during trading on Monday. The company traded as low as $1.72 and last traded at $1.7250. Approximately…
Orexo AB (publ) proposes SEK250M rights issue ahead of drug milestones
Orexo expects to announce final issue terms preliminarily on Nov. 3 and plans a shareholder vote for Nov. 6. An approximately SEK250 million rights issue would finance drug development and a possible U.S. Justice Department settlement…
Eloxx Pharmaceuticals (ELOX) and Its Rivals Critical Comparison
Posted by Kim Johansen on Oct 1st, 2026 Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) is one of 902 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Eloxx Pharmaceuticals…
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Short Interest Update
Get Our Latest Stock Report on Eloxx Pharmaceuticals Eloxx Pharmaceuticals (NASDAQ:ELOX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter.…
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
marketscreener.com Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan…
Analyzing Eloxx Pharmaceuticals (NASDAQ:ELOX) & LENZ Therapeutics (NASDAQ:LENZ)
Posted by Mitch Edgeman on Sep 29th, 2026 LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) and Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of ... Immix Biopharma Announces Pricing of…
From articles in the 4Search news index.
In the news
Mentioned with
Most coverage from
-
themarketsdaily.com2
-
bioxconomy.com1
-
defenseworld.net1
-
lufkindailynews.com1
-
manilatimes.net1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.